Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oxidative Stress Modulation and Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NFE2L2/NRF2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NFE2L2 Recombinant Protein (Neh2 Domain / Full Length, WT & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. Includes KEAP1-resistant mutants (DLG/ETGE). |
View NFE2L2 Products |
| Gene Delivery | NFE2L2 Promise-ORF / Lentivirus & ARE-Reporter Lentivirus Full-length ORF for stable cell lines with native glycosylation. Constitutive or inducible. |
View NFE2L2 Products |
| Benchmark Ab | Anti-NFE2L2 Antibody (Recombinant Rabbit mAb for WB/ChIP/IP/ICC) Recombinant positive control for detection. |
View NFE2L2 Products |
| Validator | NFE2L2 siRNA Set For knockdown verification and specificity controls. |
View NFE2L2 Products |
| Related Target: KEAP1 | KEAP1 Kelch Domain Protein E3 ligase adapter; Direct binding partner for PPI assays (SPR, AlphaLISA, ITC). |
View KEAP1 Products |
| Related Target: SQSTM1 | SQSTM1/p62 Recombinant Protein Competitive binder; Autophagy crosstalk validation. |
View SQSTM1 Products |
| Related Target: CUL3 | CUL3 Recombinant Protein E3 ubiquitin ligase scaffold; Complex formation studies. |
View CUL3 Products |
| Related Target: HMOX1 | HMOX1 Recombinant Protein Direct downstream effector biomarker for NRF2 activation. |
View HMOX1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PPI Disruption (KEAP1-NRF2 Interface) | High-purity Neh2 domain protein (>95%) with verified ETGE/DLG motifs for FP/SPR/ITC assays |
| Cancer Mutant Resistance Profiling | KEAP1 G333C, G430C, R554Q mutant proteins (Sequence Verified) for mechanistic bypass studies |
| Transcriptional Activity Screening | Lentiviral ARE-Luciferase reporter particles for stable cell line construction; Endotoxin controlled |
| Selectivity vs Other bZIP Family | Parallel availability of MAF, BACH1 proteins (>95% purity) for counter-screening |
| False Positives in Functional Assays | Validated NFE2L2 siRNA included for target specificity verification |
| Distinguishing Nrf2 from paralogs (NFE2L1, NFE2L3, BACH1) | Nrf2-specific degron-containing antigens; Theoretical MW confirmed; counter-screening proteins available. |
Live NFE2L2/NRF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The NFE2L2/NRF2 axis presents a unique therapeutic paradox driving bifurcated R&D strategies. In metabolic and neurodegenerative diseases, the race is intensifying to develop selective activators that disrupt the KEAP1-NRF2 interaction without the off-target electrophilicity of first-generation agents like dimethyl fumarate. Conversely, in oncology, the recognition of KEAP1 mutations as oncogenic drivers has shifted focus toward specific NRF2 inhibition and targeted degradation strategies to overcome chemotherapy resistance in lung adenocarcinoma and squamous cell carcinoma. First-generation electrophilic activators (e.g., omaveloxolone) have validated the pathway but raised safety concerns around tumorigenicity and off-target cysteine reactivity. Consequently, the next wave of R&D is shifting toward non-electrophilic, direct KEAP1-Nrf2 protein-protein interaction (PPI) modulators and selective Nrf2 inhibitors that disrupt CNC-bZIP DNA binding or downstream effector transcription without pleiotropic redox stress. As the field matures, expect a surge in precision assays distinguishing cysteine-reactive pan-electrophiles from mechanism-based PPI inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NRF2 Activators (Electrophilic) | Biogen, Reata | ALS, NASH, Psoriasis, Friedreich's Ataxia, CKD | Selectivity Panel (Need KEAP1-NRF2 vs IKKβ/CRIF1 screening proteins) |
| NRF2 Activators (Non-electrophilic PPI) | Astellas, Intellia | NASH, CKD | FP/SPR Assay (Need high-purity Neh2 domain protein) |
| NRF2 Inhibitors (Direct) | Preclinical Biotechs | KEAP1-mutant Lung Cancer, Pancreatic Cancer | DNA Binding Assay (Need Neh1 bZip domain protein) |
| KEAP1 PROTACs | Arvinas, Cullgen | Solid Tumors | Ternary Complex Formation (Need full-length KEAP1 & CUL3 proteins) |
Molecular Differentiation & Assay Strategy
Activators
- Affinity & Selectivity: High-purity Neh2 domain protein (ETGE/DLG motifs) for FP/SPR/ITC assays. Must distinguish electrophilic (Cys151 modification) from non-electrophilic (direct PPI blockade) mechanisms.
- Resistance Profiling: Parallel screening with WT vs mutant KEAP1 (G333C, G430C, R554Q) to validate bypass of resistance mutations.
Inhibitors
- Mechanism Specificity: Inhibit NRF2-MAF heterodimer binding to ARE DNA without affecting other bZIP factors (BACH1, ATF4, JUN).
- Assay: EMSA with Neh1 domain protein; ARE-Luciferase reporter cell lines for high-throughput screening.
PROTACs
- Ternary Complex Formation: Full-length KEAP1, CUL3, and RBX1 proteins for in vitro ubiquitination cascade assays.
Related Targets for Cross-sell
- KEAP1: Direct E3 ligase adapter; essential for PPI assays and mutant studies.
- SQSTM1/p62: Competitive KEAP1 interactor; autophagy crosstalk validation.
- CUL3: E3 ubiquitin ligase scaffold; required for PROTAC mechanism studies.
- HMOX1: Downstream effector biomarker for NRF2 activation.
- MAF: Obligatory heterodimerization partner for NRF2; needed for selectivity assays.